Stock Market Today (LIVE): Beazer Tells Dream Finders to Dream On; CPI Comes in Hot, Gas Surges, Treasury Yield Hits 1-Year High

📌 Top story -- scroll down for more updates

4:15pm DFH -13.37% today, BZH -7.31% today

By Buck Hartzell

Beazer Homes (BZH 7.27%) rejected Dream Finders’ (DFH 13.37%) latest cash offer to purchase the company for $25.75 per share. They stated the new offer was an 11% reduction from the March 17 proposal. Beazer’s most recently reported book value was $41.83 per share. Beazer plans to sell off non-core assets worth $150 million and continue to execute their plan. Both companies sold off on the news. The deal certainly makes sense from a strategic standpoint for DFH. A quick look at the 10 year price-to-book value reveals that Beazer averages about 0.68x book value, not far from DFH’s offer of 0.61x.

4:06 pm

April CPI came in hotter than expected at 3.8% annually, driven by a gasoline surge, pushing 10-year Treasury yields to a one-year high of 4.46%. The Nasdaq is taking the worst of it: Stock Advisor (Team HG) rec Intel (INTC 6.79%), Qualcomm (QCOM 11.61%), and Micron (MU 3.75%) are each off 4% or more, while the S&P 500 and Dow are near flat.

3:44 pm — UPS -1.13%

Amazon (AMZN 1.19%) just announced it’s opening its legendary delivery machine to every business on the planet — and UPS (UPS 1.56%) investors are not thrilled. UPS stock is already down 50%-plus over five years, and now it has a trillion-dollar rival muscling into its lane. "I'm glad I sold all my UPS stock when I retired in 2020," yamablasterx2 wrote last week. Consider this, though: UPS has already been dumping Amazon as a customer to chase better margins. It's hard to lose a customer you were already kicking out.

3:11 pm — ASTS -12.37%

AST SpaceMobile (ASTS 11.62%) fell 13% Tuesday after Q1 results that, to put it gently, were not great. Analysts wanted $0.21 in losses per share on $37.5M in revenue. They got $0.66 in losses on $14.7M. The silver lining is that revenue grew 20-fold year over year. The less-silver lining: free cash flow was negative $427.4M.

2:56 pm — UNFI -1.24%

Quantedge Capital just decided 85% was enough. The fund disclosed an SEC filing showing it sold its entire United Natural Foods (UNFI 2.18%) stake in Q1 — roughly 88,000 shares worth an estimated $3.37 million. UNFI has outrun the S&P 500 by nearly 60 percentage points over the past year. Motley Fool analyst Rich Greifner recently wrote, "The company is intentionally sacrificing lower-margin conventional grocery sales to focus on natural, organic, and specialty products, which carry better margins and stronger growth potential.

2:26 pm — LIF -12.82%

Life360 (LIF 10.77%) crushed Q1 estimates — 38% revenue growth, raised guidance, the works — and the market’s response was to knock shares down 11%. The culprit: an Android registration glitch that dinged monthly active user growth. CEO Lauren Antonoff says demand never faded, and the company isn’t sweating the long-term outlook.

1:35 pm -- ONON -2.2%

By Sanmeet DeoTeam Rule Breakers

On Holding (ONON 0.40%) just delivered one of its strongest quarters ever -- and the market's reaction tells you everything about where investor psychology sits today.

Here's what happened. On crossed the CHF 800 million quarterly sales mark for the first time, growing 26.4% at constant currency in Q1 2026. The more important story, though, was profitability. Gross margin surged 430 basis points to a record 64.2% -- achieved despite meaningful U.S. tariff headwinds -- while adjusted EBITDA margin hit 21%, up 450 basis points year-over-year. Average selling prices climbed from roughly $145 to over $170. Asia-Pacific crossed 20% of global sales for the first time, growing 61.4% at constant currency, with China expanding at high double digits and an apparel penetration rate of 30% compared to just 6% companywide. Apparel also exceeded 10% of direct-to-consumer sales for the first time. These are milestones, not noise.

So what does it mean? The margin story is the real headline. Management explicitly called 64.5% the new gross margin baseline -- not a peak -- and raised full-year profitability guidance meaningfully. That reprices On's long-run earnings power. The APAC and apparel momentum together address the two most persistent bear concerns: geographic concentration and category dependency.

1:30 pm -- TSLA -4.1%

Tesla (TSLA 2.60%) shares slipped after a five-session run that pushed the stock up nearly 15%, as investors looked ahead to CEO Elon Musk's trip to China with President Trump on Thursday. The visit comes alongside meetings between U.S. and China trade delegations and a separate sit-down with President Xi Jinping that also includes Boeing (BA 0.44%) CEO Kelly Ortberg and Apple (AAPL +0.73%) CEO Tim Cook.

12:40 pm

The Senate confirmed Kevin Warsh as a Federal Reserve governor Tuesday in a 51-45 vote, clearing the path for him to be named Chair on Wednesday. Warsh succeeds Jerome Powell, who exits Friday as inflation hits a three-year high driven by the Iran war and new tariffs. While Warsh has advocated for "regime change" and signaled that interest rates could be lower, he takes the helm of the central bank during a period of intense price pressure. Though Powell will remain on the board until 2028 to oversee an internal probe, Warsh’s leadership represents a potential pivot in monetary policy that could shift the outlook for dividend-paying giants like Coca-Cola (KO +1.74%) and high-growth tech leaders such as Microsoft (MSFT 1.21%).

11:20 am -- NVO -0.4%

Novo Nordisk (NVO +1.29%) released clinical data Tuesday showing its 7.2-milligram high-dose Wegovy enabled "early responders" to lose an average of 27.7% of their body weight over 72 weeks. This analysis, presented at the European Congress on Obesity, aims to neutralize the efficacy advantage held by Eli Lilly (LLY +2.37%) and its rival drug Zepbound. While the broader trial group averaged 21% weight loss, the performance of these rapid responders — about one in four patients — provides a potent marketing tool as Novo fights to win back market share. Three major U.S. pharmacy benefit managers have already added the higher dose to standard formularies, accelerating the rollout of this competitive extension.

11:15 am -- HIMS -12.4%

By Sanmeet DeoTeam Rule Breakers

Hims & Hers Health (HIMS 14.10%) just delivered its worst GAAP quarter since going public, and the market is punishing it accordingly -- shares are down roughly 12% today. Revenue grew just 4% year-over-year to $608 million, a brutal deceleration from 111% growth a year ago, while a net loss of $92 million erased all the hard-won profitability the company had built. The immediate pain comes from Q2 EBITDA guidance actually lower than what was just reported, with gross margins guided to compress further still. Investors who chased the stock up 50% in the prior month are getting a cold shower instead.

The so-what is that almost all of this damage was deliberate. Hims walked away from its compounded semaglutide business overnight and relaunched with branded Wegovy and Zepbound. Within six weeks, 125,000+ shipments were fulfilled and the company is tracking to add over 100,000 new weight-loss subscribers per month, demand the CFO said exceeded even the Super Bowl campaigns. Full-year revenue guidance was raised to $2.8–$3.0 billion, and the CFO stated branded and compounded unit economics are "roughly comparable" on a dollar basis, meaning this is a timing problem, not permanent margin destruction.

10:15 am -- AMZN -1.5%

Amazon (AMZN 1.19%) is launching "Amazon Now," a service delivering packages in 30 minutes or less across dozens of U.S. cities. Utilizing a network of micro-fulfillment "dark stores" and Flex drivers, the retail giant aims to reach tens of millions of customers by year-end. This aggressive move directly challenges gig-economy rivals like DoorDash (DASH 1.35%) and Uber (UBER +0.28%) by offering 24/7 access to everything from electronics to groceries. CEO Andy Jassy maintains that ultra-fast speeds drive higher conversion and customer retention, effectively turning logistics into a competitive weapon against brick-and-mortar leader Walmart (WMT +2.16%).

10:10 am -- HIMS -9.9%

Hims & Hers Health (HIMS 14.10%) shares tanked by up to 15% Tuesday as the telehealth firm’s first-quarter net loss nearly doubled to $92 million. While revenue nudged up 4% to $608 million, investors were spooked by a significant drop in adjusted EBITDA and a lowered outlook. The company is navigating a painful transition after settling with Novo Nordisk (NVO +1.29%) to stop selling cheap, compounded versions of weight-loss drugs like Wegovy. Under the new pact, Hims will sell branded GLP-1s but must cease the "mass compounding" that previously fueled its margins. With revenue per subscriber slipping to $80, the firm faces a steep uphill climb to prove its business model works without patented shortcuts.

9:35 am -- MU -4.5%, AMD -1.3%, QCOM -5.7%

The S&P 500 pulled back from record highs Tuesday after April’s Consumer Price Index hit 3.8%, its highest annual level since 2023. This hotter-than-expected data, driven by West Texas Intermediate futures surging past $100, sparked a sell-off in high-flying tech names. Micron Technology (MU 3.75%) reversed its recent 37% weekly surge with a 4% drop, dragging peers Advanced Micro Devices (AMD 2.27%) and Qualcomm (QCOM 11.61%) lower. With President Trump declaring the U.S.-Iran ceasefire on "massive life support," investors are bracing for a persistent energy-driven inflation story that could dominate the remainder of the year.

9:10 am -- ZBRA +13.5% in pre-market trading

By Jason MoserTeam Rule Breakers

Zebra Technologies (ZBRA +11.46%) reported encouraging first-quarter results with a 14.3% increase in net sales and non-GAAP earnings of $4.75 up better than 18%. The company demonstrated robust demand across both its Connected Frontline and Asset Visibility & Automation segments with segment sales up 21% and 7% respectively and there's no doubt the market is pleased w